Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Inflation Anxiety, XRP Fake News Keep Crypto Market Muted
-
Volcon Soars As Co. Gets $100 Mln Pre-orders For Its Fully Electric UTV
-
Scholastic Shares Fall 20% Following Wider Loss In Q3
-
Elon Musk’s $1 Billion Bitcoin Sale From Tesla’s Bag Is A Drop In The Ocean – Binance Chief CZ
-
Bitcoin ($BTC) Price Mirroring Previous Bottom Formations, Says Popular Crypto Analyst